Document is current
Any future updates will be listed below
-
Authors
Capparelli, Claudia
Purwin, Timothy J. http://orcid.org/0000-0002-7053-8039
Glasheen, McKenna http://orcid.org/0000-0001-5651-2345
Caksa, Signe http://orcid.org/0000-0002-0133-0015
Tiago, Manoela
Wilski, Nicole http://orcid.org/0000-0003-0285-0853
Pomante, Danielle
Rosenbaum, Sheera
Nguyen, Mai Q.
Cai, Weijia http://orcid.org/0000-0003-1469-8991
Franco-Barraza, Janusz
Zheng, Richard
Kumar, Gaurav
Chervoneva, Inna http://orcid.org/0000-0002-9104-4505
Shimada, Ayako http://orcid.org/0000-0002-9941-7660
Rebecca, Vito W.
Snook, Adam E. http://orcid.org/0000-0001-9216-4560
Hookim, Kim
Xu, Xiaowei
Cukierman, Edna http://orcid.org/0000-0002-1452-9576
Herlyn, Meenhard http://orcid.org/0000-0003-0839-0739
Aplin, Andrew E. http://orcid.org/0000-0002-2734-3244
- License Information
-
More Information
Article History
Received: 8 June 2021
Accepted: 7 February 2022
First Online: 16 March 2022
Competing interests
: A.E.A. reports receiving a commercial research grant from Pfizer Inc. (2013-2017) and has ownership interest in patent number 9880150. E.C. wishes to disclose that she is currently a consultant and SAB member for Phenomic AI. X.X. is the co-founder and shareholder of CureBiotech, Inc, and Exio Bioscience and he also did consultant work for BMS. The remaining authors declare no competing interests.
